🚀 Is this Quiet $10M Company a $2B Opportunity?

This Energy Source Will Eclipse Oil and Gas... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from i2i Marketing Group, LLC    Dear Investor, Imagine owning a company with assets worth over $80 million... while its market cap is less than $10 million. Potentially an easy 8x for investors. But it gets better... This undervalued gem has quietly secured rights to a massive energy deal. Worth up to $2 billion in revenue over the next decade. I'm not even sure this is public knowledge. Because so few investors are paying attention. That's the kind of hidden value that we try to bring you with these alerts. If word gets out, this company's valuation could skyrocket. Click here for the full name and ticker symbol of this hidden giant. Sincerely, Editor This message is a PAID ADVERTISEMENT for NU E Power Corp (NUEPF) from i2i Marketing Group, LLC. StockEarnings, Inc. has received a fixed fee of $7500 from i2i Marketing Group, LLC for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between March 12, 2025 and March 18, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NU E Power Corp (NUEPF) or i2i Marketing Group, LLC. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NU E Power Corp (NUEPF) on Edge on the street website for additional information about the relationship between i2i Marketing Group, LLC and NU E Power Corp (NUEPF). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

GeoVax Labs, Inc. (Nasdaq: GOVX) Triggers 17 Bullish Signals Making New Daily High—You Watching This?

*Sponsored Krypton Street Announces Its Next Potential Breakout Idea! Here’s What We Can Tell You About GeoVax Labs, Inc. (Nasdaq: GOVX)—So Far: Limited Float: GeoVax Labs, Inc. (Nasdaq: GOVX) Has Around 10M Shares Available, Meaning Even A Small Shift In Demand Could Create The Potential For Significant Swings. Under The Radar: With A Market Cap Of Approximately $15M As Of 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) Appears To Be Flying Under  Wall Street’s Radar—For Now. Analyst Coverage: Analysts Highlight GeoVax Labs, Inc. (Nasdaq: GOVX), With One Target Suggesting A 1,039% Upside Potential. Advancing Pipeline: GeoVax Labs, Inc. (Nasdaq: GOVX) Is Progressing With Gedeptin In Phase 2 Trials And GEO-CM04S1 In Active Development. Potential For $37B+ Market Growth: With The Biodefense Sector Expected To Surpass $37.16B By 2034, GeoVax Labs, Inc. (Nasdaq: GOVX) Aligns With A Rapidly Growing Industry. Keep reading to get up to speed on GeoVax Labs, Inc. (Nasdaq: GOVX) and see why it’s topping our watchlist for Wednesday morning. March 12, 2025 Dear Reader, Well… Well… Well… Can you say “Bullish Momentum?”  GeoVax Labs, Inc. (Nasdaq: GOVX) just triggered 17 Bullish Signals on TradingView’s technical analysis tool, including the “Momentum Indicator" on the 15-minute time frame.  And get this. (GOVX) just made a new daily high of $1.73, marking an approximate 13% early move from yesterday’s $1.53 low.  Earlier today, the company announced its expansion into Europe, establishing its initial footprint in the UK. This expansion strengthens GeoVax Labs, Inc. (Nasdaq: GOVX)’s global presence, reinforcing collaborations with top scientists, academic institutions, and manufacturing partners across the region.  It’s also expected to support the advancement of Gedeptin, currently in clinical trials for head and neck cancers, while furthering development across its vaccine and immunotherapy pipeline. With momentum building on multiple fronts, GeoVax Labs, Inc. (Nasdaq: GOVX) is turning heads at a pivotal moment. If you missed my previous email, keep reading to get up to speed and see why were so excited to bring you GeoVax Labs, Inc. (Nasdaq: GOVX). The biotech and pharma space moves fast—one breakthrough can take a little-known company from obscurity to the spotlight in no time. We are now turning our attention to GeoVax Labs, Inc. (Nasdaq: GOVX) and have it at the top of our watchlist this morning. (3/12/2025)  With a mission to address critical health concerns, GeoVax Labs, Inc. (Nasdaq: GOVX) is developing solutions for some of the most pressing medical challenges through cutting-edge science and strategic vision. Flying Under The Radar With an Approximate $15M Market Cap, Analyst’s Target Suggests 1,039% Upside Potential… Analyst coverage clearly highlights GeoVax Labs, Inc. (Nasdaq: GOVX)’s considerable upside potential: According to Benzinga, D. Boral Capital has assigned an $18 target to (GOVX), which suggests over 1,039% upside potential from today’s $1.58 range.  Additionally, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, maintains a Bullish rating with a $12 target, underscoring GeoVax Labs, Inc. (Nasdaq: GOVX)’s clinical momentum.  LeBoyer notes that Gedeptin’s progress into Phase 2 trials is in line with expectations and highlights CM-04S1 as aiming to provide enhanced protection compared to existing options, with key clinical data anticipated in the first half of 2025. Noble Capital Markets bases its $12 target on projected fiscal year 2026 earnings per share (EPS) of $1.45, discounted at 30% annually to reflect risks associated with the industry and market.  The firm also assigns GeoVax Labs, Inc. (Nasdaq: GOVX) an 'Above Average' fundamental rating, pointing to the company’s experienced management team, robust corporate governance, and strong competitive positioning. As of yesterday's date, 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) has a market cap of approximately $15M and a public float below 10M shares.  Companies with such small market capitalization and limited float often have significant growth potential, particularly if attention begins to increase. Continue reading to discover why GeoVax Labs, Inc. (Nasdaq: GOVX) will be at the top of our watchlist tomorrow morning. GeoVax Labs, Inc. (Nasdaq: GOVX) Strengthens Its Clinical Pipeline With Key Developments… GeoVax Labs, Inc. (Nasdaq: GOVX) is engaged in developing next-generation treatments and therapies.  Its leading clinical candidate, GEO-CM04S1, has demonstrated enhanced immune responses in individuals with specific health conditions, such as Chronic Lymphocytic Leukemia (CLL).  This advancement aims to provide stronger immunity where it is needed most. Another notable project is GEO-MVA, designed to address multiple strains of a global health concern.  Given the increasing demand for innovative solutions in public health, this approach provides an avenue for broader protection.  GeoVax Labs, Inc. (Nasdaq: GOVX)’s  research in oncology is also progressing, with Gedeptin currently in Phase 2 clinical trials.  This therapy explores new methods of targeting cancer cells and improving patient outcomes. GeoVax Labs, Inc. (Nasdaq: GOVX) has also announced that its Phase 2 trial for Gedeptin, its gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN), is expected to begin in the first half of 2025.  This therapy employs Gene-Directed Enzyme Therapy (GDEPT) technology, which enhances the effectiveness of treatment while minimizing its impact on surrounding healthy cells.  The trial will explore Gedeptin’s use in combination with immune-based therapies, supporting a multi-faceted approach to treatment. Beyond its clinical pipeline, GeoVax Labs, Inc. (Nasdaq: GOVX) is also working to address broader national and global health concerns.  With a focus on strengthening preparedness efforts, the company is advancing technologies that align with the increasing demand for biodefense solutions. Biodefense Spending Is Expected to Exceed $37B—GeoVax Labs, Inc. (Nasdaq: GOVX) Eyes Role in Future Advancements The global biodefense market is on a significant growth trajectory, expected to reach $19.22B in 2025 and surpass $37.16B by 2034.  The U.S. alone is projected to account for approximately $10.87B of this market, driven by increasing awareness of biological threats and the need for stronger preventive measures.  In 2023, North America contributed over 41% of global biodefense revenue, and this share is expected to expand as governments continue investing in national security and public health infrastructure.  With well-established production facilities and strategic programs aimed at mitigating risks, the U.S. remains a key player in advancing technologies that enhance preparedness and response capabilities. GeoVax Labs, Inc. (Nasdaq: GOVX) has underscored the role of its Modified Vac-cin-ia Ankara (MVA) platform in supporting these efforts and helping to bolster U.S. biodefense capabilities.  By aligning with key recommendations from the "Bolstering U.S. Biodefense" report, the company is working to address critical gaps in medical preparedness and contribute to the resilience of national health initiatives. Several aspects of GeoVax Labs, Inc. (Nasdaq: GOVX)’s ongoing initiatives directly support these national security objectives: Enhancing Supply Chain Security: GeoVax is reducing reliance on foreign manufacturing by transitioning to a next-generation production platform designed to strengthen domestic capabilities. Improving Readiness for Emerging Health Concerns: The development of adaptable solutions ensures preparedness for evolving challenges and strengthens overall response frameworks. Supporting Public Health Infrastructure: GeoVax’s research and development efforts align with national and global health strategies aimed at expanding medical capabilities. Advancing Scalable Medical Solutions: By refining platforms that allow for rapid response and large-scale production, GeoVax is working to ensure greater accessibility and efficiency in health preparedness efforts. Expanding Areas of Focus The need for advanced medical solutions continues to grow, providing multiple areas where GeoVax’s work may be impactful: Immune-Compromised Populations: GEO-CM04S1 is being evaluated for its ability to strengthen immune responses in targeted groups. Public Health & Safety: As certain health concerns persist worldwide, GEO-MVA is positioned to play a role in broad-scale protection efforts. Oncology Research: With a growing focus on immune-based treatments, GeoVax’s work in this field has the potential to contribute to new advancements in cancer care. Recent Developments and Strategic Initiatives GeoVax has remained proactive in responding to critical health concerns and forming partnerships that support its research. Recent developments include: Global Health Preparedness: GeoVax has acknowledged ongoing public health challenges and remains focused on addressing them through its scientific advancements. Focus on MVA-Based Platforms: The company continues to refine its Modified Vac-cin-ia Ankara (MVA)-based research, aiming to enhance effectiveness across multiple applications. Monitoring Emerging Health Trends: With new concerns arising, GeoVax is staying ahead by ensuring its developments align with current and future needs. Commitment to Accessibility: GeoVax has emphasized its goal of making its advancements widely available, particularly in areas where access remains limited. Clinical Progress: The company has been making strides in its programs, with its CM-04S1 candidate selected for further evaluation in a BARDA-sponsored Phase 2b study set to commence in the second half of 2025. 7 Reasons We’re Keeping an Eye on GeoVax Labs, Inc. (Nasdaq: GOVX) Early This Morning… 1. Limited Float: GeoVax Labs, Inc. (Nasdaq: GOVX) has approximately 10M shares in the float, meaning even a slight shift in demand could create the potential for significant swings. 2. Under the Radar: With a market cap of around $15M as of 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—until now. 3. Analyst Coverage: Analysts clearly highlight GeoVax Labs, Inc. (Nasdaq: GOVX)’s potential. With one analyst’s target suggesting 1,039% upside potential from today’s range. 4. Advancing Pipeline: GeoVax Labs, Inc. (Nasdaq: GOVX) is pushing forward with Gedeptin in Phase 2 trials and GEO-CM04S1 in active development. 5. Potential For $37B+ Market Growth: With the biodefense sector projected to surpass $37.16B by 2034, GeoVax Labs, Inc. (Nasdaq: GOVX) aligns itself with a rapidly expanding space. 6. Government Initiatives: The Bolstering U.S. Biodefense Report emphasizes the need for enhanced medical readiness, aligning with GeoVax Labs, Inc. (Nasdaq: GOVX)’s ongoing efforts. 7. Supply Chain Security: GeoVax Labs, Inc. (Nasdaq: GOVX) aims to strengthen domestic capabilities and reduce reliance on foreign production. Consider Adding GeoVax Labs, Inc. (Nasdaq: GOVX) To Your  Radar This Morning… Let’s be honest—GeoVax Labs, Inc. (Nasdaq: GOVX) isn’t on everyone’s radar… yet.  But those who are paying attention might be ahead of the curve. While most people chase what’s already made headlines, this one appears to be still flying under the radar——and if history is any guide, this is where some of the most interesting moves tend to start. Here’s what stands out: A biopharma advancing next-generation treatments with a pipeline pushing into Phase 2. A sector projected to exceed $37B, backed by increasing government focus. A tiny market cap and float, which historically have led to the potential for significant swings if demand starts to shift.  And let’s not overlook the analysts—one has set an $18 target, another is at $12—both signaling what could be significant upside potential from here. So what’s next?  We have all eyes on GeoVax Labs, Inc. (Nasdaq: GOVX) right now. Consider taking a look at (GOVX) this morning while it’s still early— and remember to do your own research. GeoVax Labs, Inc. (Nasdaq: GOVX) tops today’s watchlist—take a look while it’s still early. GeoVax Labs, Inc. (Nasdaq: GOVX) just triggered 17 Bullish Signals on TradingView’s technical analysis tool, including the “Momentum Indicator" on the 15-minute time frame.  And get this… (GOVX) also just made a new daily. Are you watching this yet?  Please make sure you keep a look out for my next update—could be on its way shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/11/2025 and ending on 03/12/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC, or their members own shares of (GOVX:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/govx/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice

GeoVax Labs (Nasdaq: GOVX) Lights Up 17 Bullish Signals On Move To New Daily High

*Sponsored Just Announced! GeoVax Labs (Nasdaq: GOVX) Tops Our Early Morning Watchlist—Take Look While It’s Still Early… This Profile Comes Backed By Several Potential Catalysts Including: With a market cap of approximately $15M as of 3/11/2025, GeoVax Labs (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—for now. GeoVax Labs (Nasdaq: GOVX) has around 10M shares available, meaning even a small shift in demand could create the potential for significant swings. Analysts highlight GeoVax Labs (Nasdaq: GOVX), with one target suggesting a 1,039% upside potential. Here’s why GeoVax Labs (Nasdaq: GOVX) has earned a top spot on this morning’s watchlist March 12, 2025 Dear Reader, Please tell me you’re seeing this… GeoVax Labs (Nasdaq: GOVX) just made a new daily high of $1.73, marking an approximate 13% early move from yesterday’s $1.53 low. GeoVax Labs (Nasdaq: GOVX) is lighting up 17 Bullish Signals on TradingView’s technical analysis tool, including the “Momentum Indicator" on the 15-minute time frame.  This is on the heels of GeoVax Labs (Nasdaq: GOVX)’s breaking news that was just announced this morning.  Earlier today, the company announced its expansion into Europe, establishing its initial footprint in the UK. This expansion strengthens GeoVax Labs (Nasdaq: GOVX)’s global presence, reinforcing collaborations with top scientists, academic institutions, and manufacturing partners across the region.  It’s also expected to support the advancement of Gedeptin, currently in clinical trials for head and neck cancers, while furthering development across its vaccine and immunotherapy pipeline. With momentum building on multiple fronts, GeoVax (Nasdaq: GOVX) is turning heads at a pivotal moment.  If you missed my previous email, keep reading to get up to speed and see why were so excited to bring you GeoVax Labs (Nasdaq: GOVX). Biotech and pharma can move fast. One major development can turn a little-known company into a headline name practically overnight. This time, our attention is on GeoVax Labs (Nasdaq: GOVX)—and it’s locked in at the top of our watchlist this morning. ( Wednesday, (3/12/2025). With a mission to address critical health concerns, GeoVax Labs (Nasdaq: GOVX) is developing solutions for some of the most pressing medical challenges through cutting-edge science and strategic vision. Analyst’s Target Suggests 1,039% Upside Potential For  This Little-Known Biotech… Analyst coverage clearly highlights GeoVax Labs (Nasdaq: GOVX)’s considerable upside potential: According to Benzinga, D. Boral Capital has assigned an $18 target to (GOVX), which suggests over 1,039% upside potential from today’s $1.58 range. Additionally, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, maintains a Bullish rating with a $12 target, underscoring GeoVax Labs (Nasdaq: GOVX)’s clinical momentum.  LeBoyer notes that Gedeptin’s progress into Phase 2 trials is in line with expectations and highlights CM-04S1 as aiming to provide enhanced protection compared to existing options, with key clinical data anticipated in the first half of 2025. Noble Capital Markets bases its $12 target on projected fiscal year 2026 earnings per share (EPS) of $1.45, discounted at 30% annually to reflect risks associated with the industry and market.  The firm also assigns GeoVax Labs (Nasdaq: GOVX) an 'Above Average' fundamental rating, pointing to the company’s experienced management team, robust corporate governance, and strong competitive positioning. As of yesterday, 3/11/2025, GeoVax Labs (Nasdaq: GOVX) has a market cap of approximately $15M and a public float below 10M shares.  Companies with such small market capitalization and limited float often have significant growth potential, particularly if attention begins to increase. Continue reading to discover why GeoVax Labs (Nasdaq: GOVX) is at the top of our early morning watchlist. GeoVax Labs (Nasdaq: GOVX) Advances Next-Gen Therapies With \Promising Clinical Pipeline GeoVax Labs (Nasdaq: GOVX) is engaged in developing next-generation treatments and therapies.  Its leading clinical candidate, GEO-CM04S1, has demonstrated enhanced immune responses in individuals with specific health conditions, such as Chronic Lymphocytic Leukemia (CLL).  This advancement aims to provide stronger immunity where it is needed most. Another notable project is GEO-MVA, designed to address multiple strains of a global health concern.  Given the increasing demand for innovative solutions in public health, this approach provides an avenue for broader protection.  GeoVax Labs (Nasdaq: GOVX)’s  research in oncology is also progressing, with Gedeptin currently in Phase 2 clinical trials.  This therapy explores new methods of targeting cancer cells and improving patient outcomes. GeoVax Labs (Nasdaq: GOVX) has also announced that its Phase 2 trial for Gedeptin, its gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN), is expected to begin in the first half of 2025.  This therapy employs Gene-Directed Enzyme Therapy (GDEPT) technology, which enhances the effectiveness of treatment while minimizing its impact on surrounding healthy cells.  The trial will explore Gedeptin’s use in combination with immune-based therapies, supporting a multi-faceted approach to treatment. Beyond its clinical pipeline, GeoVax Labs (Nasdaq: GOVX) is also working to address broader national and global health concerns.  With a focus on strengthening preparedness efforts, the company is advancing technologies that align with the increasing demand for biodefense solutions. GeoVax Labs (Nasdaq: GOVX) Aligns With Market Trends as Biodefense Sector In the U.S. Alone Poised to Break $10B—And Over $37B Globally… The global biodefense market is on track to reach $19.22B in 2025 and surpass $37.16B by 2034, with the U.S. projected to account for $10.87B.  In 2023, North America contributed 41% of global revenue, a share expected to grow as governments expand investments in national security and public health. GeoVax Labs (Nasdaq: GOVX) is advancing its Modified Vaccinia Ankara (MVA) platform to support these efforts, aligning with key recommendations from the Bolstering U.S. Biodefense report.  The company is addressing critical gaps in medical preparedness and reinforcing national health initiatives by: Strengthening Supply Chains: Transitioning to domestic production to reduce reliance on foreign manufacturers. Enhancing Readiness: Developing adaptable solutions for emerging health threats. Supporting Public Health: Aligning research with global strategies to expand medical capabilities. Scaling Solutions: Refining platforms for rapid response and large-scale production to improve accessibility and efficiency. Expanding Focus & Recent Developments GeoVax Labs (Nasdaq: GOVX) is advancing medical solutions across key areas: Immune-Compromised Populations: GEO-CM04S1 is being evaluated for its potential to enhance immune responses in targeted groups. Public Health & Safety: GEO-MVA is positioned for broad-scale protection as global health concerns persist. Oncology Research: GeoVax continues exploring immune-based treatments, contributing to advancements in cancer care. Recent Developments & Strategic Moves Health Preparedness: GeoVax remains focused on addressing public health challenges through innovation. MVA-Based Research: Ongoing efforts aim to enhance the effectiveness of its Modified Vaccinia Ankara (MVA) platform. Emerging Trends: The company continuously aligns its work with evolving medical needs. Accessibility Commitment: GeoVax prioritizes making its advancements widely available, especially in underserved areas. Clinical Progress: CM-04S1 is moving forward in a BARDA-sponsored Phase 2b study set to begin in the second half of 2025. 7 Reasons We’re Keeping an Eye on GeoVax Labs (Nasdaq: GOVX) This Morning… 1. Under the Radar: With a market cap of around $15M as of 3/11/2025, GeoVax Labs (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—until now. 2. Limited Float: GeoVax Labs (Nasdaq: GOVX) has approximately 10M shares in the float, meaning even a slight shift in demand could create the potential for significant swings. 3. Advancing Pipeline: GeoVax Labs (Nasdaq: GOVX) is pushing forward with Gedeptin in Phase 2 trials and GEO-CM04S1 in active development. 4 Government Initiatives: The Bolstering U.S. Biodefense Report emphasizes the need for enhanced medical readiness, aligning with GeoVax Labs (Nasdaq: GOVX)’s ongoing efforts. 5. Supply Chain Security: GeoVax Labs (Nasdaq: GOVX) aims to strengthen domestic capabilities and reduce reliance on foreign production. 6. Potential For $37B+ Market Growth: With the biodefense sector projected to surpass $37.16B by 2034, GeoVax Labs (Nasdaq: GOVX) aligns itself with a rapidly expanding space. 7. Analyst Coverage: Analysts clearly highlight GeoVax Labs (Nasdaq: GOVX)’s potential. With one analyst’s target suggesting 1,039% upside potential from today’s range.  Consider Adding GeoVax Labs (Nasdaq: GOVX) To Your  Radar This Morning… Now I have to tell you—GeoVax Labs (Nasdaq: GOVX) isn’t on everyone’s radar… yet.  But those who are paying attention might be ahead of the curve. While most people focus on names that have already grabbed headlines, this one is still flying under the radar—and if history tells us anything, early attention is where some of the most interesting setups begin. Here’s what makes this one stand out: A biopharma developing next-generation treatments, with a pipeline advancing into Phase 2. A sector projected to exceed $37B, fueled by growing government focus. A tiny market cap and low float, conditions that have historically led to significant moves when interest starts to build. Analyst targets pointing as high as $18, with another at $12—both suggesting the potential significant upside.  What happens next?  We have all eyes on GeoVax Labs (Nasdaq: GOVX) this morning. Consider taking a look at (GOVX) while it’s still early—and as always, do your own research.  GeoVax Labs (Nasdaq: GOVX) just made a new daily high of $1.73, marking an approximate 13% early move from yesterday’s $1.53 low. GeoVax Labs (Nasdaq: GOVX) is lighting up 17 Bullish Signals on TradingView’s technical analysis tool, including the “Momentum Indicator" on the 15-minute time frame. Please tell me you’re seeing this right now.  My next update could be out shortly—so keep a look out for it. Sincerely, Jeff Ackerman Managing Editor Stock News Trends Click to connect no-cost SMS (takes less than 20 seconds) StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and LFG Equities Corp., TD Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/12/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, TD Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid forty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC, Media 1717 LLC, or their members own shares of (GOVX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/govx/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice